Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Cancer · 2019 · PMC6771856 · PMID 31173362

Europe PMC DOI

hedged sentence

0.0960

closest p · 1.9× alpha

0.0960

boldest claim

The sentences

did not reach statistical significanceP = .096so close (0.05 < p ≤ 0.1)

The CBR among LPS patients, although similar in magnitude, did not reach statistical significance (28% vs 15% for trabectedin vs dacarbazine; P = .096) (Supporting Table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.